Fig. 2From: Novel mutations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeuticsInteractions between GRL0617 inhibitor and superimposed SARS-CoV-2 wild type and mutant papain-like viral proteases (a–d). Interacting amino acid residues in wild-type and PLPro mutant SARS-CoV-2. Inhibitor binding into the wild type and mutant protein. The red and blue boxes indicate the location and the interactions between ligand and receptors in wild and in mutant proteases, respectivelyBack to article page